Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMevastatin
Description: HMG-CoA reductase inhibitor
Alternative Names: Compactin
Chemical Name: (2S)-2-Methyl-(1S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl butanoate
Purity: ≥98% (HPLC)
Biological Activity for Mevastatin
Mevastatin is an inhibitor of HMG-CoA reductase; decreases cholesterol biosynthesis, in vitro and in vivo. Induces apoptosis, arrests cancer cells in G1 phase and downregulates cdk 2, 4, and 6, cyclin D1 and E1, p21 and p27. Inactive lactam prodrug of mevastatin hydroxy acid, naturally bioactivated in vivo following oral administration.
Technical Data for Mevastatin
| M. Wt | 390.52 |
| Formula | C23H34O5 |
| Storage | Store at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 73573-88-3 |
| PubChem ID | 64715 |
| InChI Key | AJLFOPYRIVGYMJ-INTXDZFKSA-N |
| Smiles | [H][C@@]12C(C=C[C@H](C)[C@@]([H])2CC[C@@]3([H])OC(C[C@]([H])(O)C3)=O)=CCC[C@@H]1OC([C@@H](C)CC)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Mevastatin
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| ethanol | 9.76 | 25 with gentle warming | |
| DMSO | 19.53 | 50 with gentle warming |
Preparing Stock Solutions for Mevastatin
The following data is based on the product molecular weight 390.52. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 5.12 mL | 25.61 mL | 51.21 mL |
| 2.5 mM | 1.02 mL | 5.12 mL | 10.24 mL |
| 5 mM | 0.51 mL | 2.56 mL | 5.12 mL |
| 25 mM | 0.1 mL | 0.51 mL | 1.02 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Mevastatin
References for Mevastatin
References are publications that support the biological activity of the product.
Amin-Hanjani et al (2001) Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32 980 PMID: 11283400
Cohen et al (1984) Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density lipoprotein-receptor activity in the human hepatoma cell line Hep G2. Biochem.J. 222 35 PMID: 6089762
Wachtershauser et al (2001) HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22 1061 PMID: 11408350
If you know of a relevant reference for Mevastatin, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Mevastatin, Mevastatin supplier, HMG-CoA, reductases, inhibitors, inhibits, statins, Compactin, Reductase, 1526, Tocris Bioscience
6 Citations for Mevastatin
Citations are publications that use Tocris products. Selected citations for Mevastatin include:
Leznicki et al (2018) Expansion of DUB functionality generated by alternative isoforms - USP35, a case study. J Cell Sci 131 PMID: 29685892
Brown and Price (2007) Characterization of Salmonella enterica serovar Typhimurium DT104 invasion in an epithelial cell line (IPEC J2) from porcine small intestine. Vet Microbiol 120 328 PMID: 17157450
Song et al (2019) A dynamic view of the proteomic landscape during differentiation of ReNcell VM cells, an immortalized human neural progenitor line. Sci Data 6 190016 PMID: 30778261
Kant et al (2019) Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease Neurons. Cell Stem Cell 24 363 PMID: 30686764
Vergnes et al (2016) SREBP-2-deficient and hypomorphic mice reveal roles for SREBP-2 in embryonic development and SREBP-1c expression. J Lipid Res 57 410 PMID: 26685326
Roche et al (2018) Trafficking of cholesterol to the ER is required for NLRP3 inflammasome activation. J Cell Biol 217 3560 PMID: 30054450
Do you know of a great paper that uses Mevastatin from Tocris? Please let us know.
Reviews for Mevastatin
There are currently no reviews for this product. Be the first to review Mevastatin and earn rewards!
Have you used Mevastatin?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cardiovascular Research Product Guide
A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:
- Hypertension
- Thrombosis and Hemostasis
- Atherosclerosis
- Myocardial Infarction
- Ischemia/Reperfusion Injury
- Arrhythmias
- Heart Failure
Cardiovascular Poster
Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.
Epilepsy Poster
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.